Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Average Price Target of $44.25 According to Brokerages

Posted by George Bondi on Nov 6th, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $44.25.

Several equities analysts have recently commented on the company. Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday, October 29th. Mizuho started coverage on Castle Biosciences in a research report on Thursday, October 29th. They set an “outperform” rating and a $60.00 price objective for the company. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a report on Friday, July 31st. Finally, BTIG Research upped their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd.

Get Our Latest Stock Analysis on Castle Biosciences

Insider Buying and Selling at Castle Biosciences

In related news, COO Kristen M. Oelschlager sold 4,153 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $35.95, for a total transaction of $149,300.35. Following the completion of the transaction, the chief operating officer owned 13,356 shares of the company’s stock, valued at approximately $480,148.20. This trade represents a 23.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin W. Juvenal sold 6,578 shares of the stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $36.42, for a total transaction of $239,570.76. Following the transaction, the insider directly owned 38,853 shares of the company’s stock, valued at $1,415,026.26. The trade was a 14.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 126,184 shares of company stock worth $4,324,506 over the last three months. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Assetmark Inc. grew its holdings in shares of Castle Biosciences by 9.3% in the first quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock valued at $142,000 after purchasing an additional 492 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Castle Biosciences by 15.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,574 shares of the company’s stock worth $194,000 after buying an additional 747 shares during the period. NFSG Corp acquired a new stake in Castle Biosciences during the 3rd quarter worth approximately $36,000. Global Retirement Partners LLC acquired a new stake in Castle Biosciences during the 2nd quarter worth approximately $26,000. Finally, Summit Global Investments lifted its holdings in Castle Biosciences by 10.9% during the 1st quarter. Summit Global Investments now owns 13,718 shares of the company’s stock worth $337,000 after buying an additional 1,353 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Stock Performance

Castle Biosciences stock opened at $34.20 on Tuesday. The firm has a 50 day simple moving average of $34.28 and a 200-day simple moving average of $28.57. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -51.82 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. Castle Biosciences has a 1-year low of $17.72 and a 1-year high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The firm had revenue of $101.95 million for the quarter, compared to analyst estimates of $92.77 million. On average, analysts expect that Castle Biosciences will post -1.29 EPS for the current year.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.